Analyst firms · Morgan Stanley · BMRN

Morgan Stanley BMRN price target and rating history

BioMarin Pharmaceutical Inc. (BMRN) · Health Care

Morgan Stanley rates BioMarin Pharmaceutical Inc. (BMRN) Overweight with a $120 price target, as of its latest action on Apr 27, 2026. It has published 4 rating actions on BMRN since November 2021, including 1 upgrade and 0 downgrades. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Morgan Stanley's $120 is 36% above that.

Current rating
Overweight
Price target
$120
Median target, all firms
$88
Actions on BMRN
4

Morgan Stanley price target on BMRN

$120$105$9020222023202420252026
Morgan Stanley price target on BMRN, each point a stated target, November 2021 to April 2026.

Every Morgan Stanley rating on BMRN

How other firms rate BMRN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$88Oct 15, 2026
Raymond JamesStrong Buy$109Oct 12, 2026
BMO Capital MarketsOutperform$98Aug 19, 2026
CitigroupBuy$75May 19, 2026
Goldman SachsNeutral$69May 11, 2026
Morgan StanleyOverweight$120Apr 27, 2026
BarclaysOverweight$80Jan 28, 2026
Canaccord GenuityBuy$98Jan 20, 2026
Leerink PartnersMarket Perform$60Dec 3, 2025

Questions about Morgan Stanley and BMRN

What is Morgan Stanley's price target for BMRN?
Morgan Stanley's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $120, from its action on Apr 27, 2026.
What is Morgan Stanley's rating on BMRN?
Morgan Stanley rates BMRN Overweight, a bullish rating, as of Apr 27, 2026.
When did Morgan Stanley last change its view on BMRN?
On Apr 27, 2026, Morgan Stanley resumes coverage at Overweight, price target $120.
How does Morgan Stanley's BMRN target compare with other analysts?
Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Morgan Stanley's $120 is 36% above that.

More BMRN rating histories

All Morgan Stanley ratingsBMRN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.